Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I have been trying to figure out

<Can you or anyone else here explain how this agreement is NOT simply a conduit for TPL to receive more proceeds from the MMP licenses before the remainder is divy'd up between the partners? >

I thought the present litigation was because of this very subject. You seem to suggest nothing will change. If that is the case, then I think there will be quite a few unhappy shareholders. But I'll wait and see, before throwing the first stone.

Opty

Share
New Message
Please login to post a reply